Randomized withdrawal of long‐term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density

References

• Neeck G. Fifty years of experience with cortisone therapy in the study and treatment of rheumatoid arthritis. Ann N Y Acad Sci 2002; 966: 28–38
   PubMed Web of Science ®Google Scholar
• Saag K. G., Criswell L. A., Sems K. M., Nettleman M. D., Kolluri S. Low‐dose corticosteroids in rheumatoid arthritis. A meta‐analysis of their moderate‐term effectiveness. Arthritis Rheum 1996; 39: 1818–25
   PubMed Web of Science ®Google Scholar
• Gotzsche P. C., Johansen H. K. Meta‐analysis of short‐term low dose prednisolone versus placebo and non‐steroidal anti‐inflammatory drugs in rheumatoid arthritis. Br Med J 1998; 316: 811–18
   PubMedGoogle Scholar
• van Everdingen A. A., Jacobs J. W., Siewertsz Van Reesema D. R., Bijlsma J. W. Low‐dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease‐modifying properties, and side effects: a randomized, double‐blind, placebo‐controlled clinical trial. Ann Intern Med 2002; 136: 1–12
   PubMed Web of Science ®Google Scholar
• Buttgereit F., Saag K. G., Cutolo M., da Silva J. A., Bijlsma J. W. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol 2005; 34: 14–21
   PubMed Web of Science ®Google Scholar
• Kirwan J. R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low‐Dose Glucocorticoid Study Group. N Engl J Med 1995; 333: 142–6
   PubMed Web of Science ®Google Scholar
• Hickling P., Jacoby R. K., Kirwan J. R. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low‐Dose Glucocorticoid Study Group. Br J Rheumatol 1998; 37: 930–6
   PubMedGoogle Scholar
• Bijlsma J. W. Can we use steroid hormones to immunomodulate rheumatic diseases? Rheumatoid arthritis as an example. Ann N Y Acad Sci 1999; 876: 366–77
   PubMedGoogle Scholar
• Saag K. G., Koehnke R., Caldwell J. R., Brasington R., Burmeister L. F., Zimmerman B., et al. Low‐dose long‐term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115–23
   PubMed Web of Science ®Google Scholar
• van Staa T. P., Leufkens H. G., Abenhaim L., Zhang B., Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39: 1383–9
   PubMed Web of Science ®Google Scholar
• Laan R. F., van Riel P. L., van de Putte L. B. Bone mass in patients with rheumatoid arthritis. Ann Rheum Dis 1992; 51: 826–32
   PubMedGoogle Scholar
• Laan R. F., van Riel P. L., van de Putte L. B., van Erning L. J., van't Hof M. A., Lemmens J. A. Low‐dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993; 119: 963–8
   PubMed Web of Science ®Google Scholar
• van Schaardenburg D., Valkema R., Dijkmans B. A., Papapoulos S., Zwinderman A. H., Han K. H., et al. Prednisone treatment of elderly‐onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment. Arthritis Rheum 1995; 38: 334–42
   PubMed Web of Science ®Google Scholar
• Michel B. A., Bloch D. A., Fries J. F. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991; 18: 804–8
   PubMed Web of Science ®Google Scholar
• Cooper C., Coupland C., Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995; 54: 49–52
   PubMedGoogle Scholar
• van Everdingen A. A., Siewertsz van Reesema D. R., Jacobs J. W., Bijlsma J. W. Low‐dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures?. Clin Exp Rheumatol 2003; 21: 155–60
   PubMed Web of Science ®Google Scholar
• Deodhar A. A., Woolf A. D. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996; 35: 309–22
   PubMedGoogle Scholar
• Verhoeven A. C., Boers M. Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol 1997; 24: 1495–503
   PubMed Web of Science ®Google Scholar
• Manolagas S. C., Weinstein R. S. New developments in the pathogenesis and treatment of steroid‐induced osteoporosis. J Bone Miner Res 1999; 14: 1061–6
   PubMed Web of Science ®Google Scholar
• Bland R. Steroid hormone receptor expression and action in bone. Clin Sci (Lond) 2000; 98: 217–40
   PubMed Web of Science ®Google Scholar
• Compston J. E., Vedi S., Mellish R. W., Croucher P., O'Sullivan M. M. Reduced bone formation in non‐steroid treated patients with rheumatoid arthritis. Ann Rheum Dis 1989; 48: 483–7
   PubMed Web of Science ®Google Scholar
• Compston J. E., Vedi S., Croucher P. I., Garrahan N. J., O'Sullivan M. M. Bone turnover in non‐steroid treated rheumatoid arthritis. Ann Rheum Dis 1994; 53: 163–6
   PubMedGoogle Scholar
• Gough A., Sambrook P., Devlin J., Huissoon A., Njeh C., Robbins S., et al. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998; 25: 1282–9
   PubMed Web of Science ®Google Scholar
• Gough A. K., Peel N. F., Eastell R., Holder R. L., Lilley J., Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 1994; 53: 14–17
   PubMed Web of Science ®Google Scholar
• Oelzner P., Franke S., Muller A., Hein G., Stein G. Relationship between soluble markers of immune activation and bone turnover in post‐menopausal women with rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 841–7
   PubMed Web of Science ®Google Scholar
• Boumpas D. T., Chrousos G. P., Wilder R. L., Cupps T. R., Balow J. E. Glucocorticoid therapy for immune‐mediated diseases: basic and clinical correlates. Ann Intern Med 1993; 119: 1198–208
   PubMed Web of Science ®Google Scholar
• Barnes P. J., Adcock I. Anti‐inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993; 14: 436–41
   PubMed Web of Science ®Google Scholar
• Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• Taves D. R. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974; 15: 443–53
   PubMed Web of Science ®Google Scholar
• World Health Organization. Report of a WHO study group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO, Technical Report Series No. 842. 1994, Geneva, Schwitzerland, WHO
   Google Scholar
• Prevoo M. L., van ‘t Hof M. A., Kuper H. H., van Leeuwen M. A., van de Putte L. B., van Riel P. L. Modified disease activity scores that include twenty‐eight‐joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8
   PubMed Web of Science ®Google Scholar
• Ekdahl C., Eberhardt K., Andersson S. I., Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988; 17: 263–71
   PubMed Web of Science ®Google Scholar
• Fries J. F., Spitz P., Kraines R. G., Holman H. R. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45
   PubMed Web of Science ®Google Scholar
• Lunar Corporation. Operator manual, expert‐XL, software version 1.7. Lunar Corporation, Madison, WI 1998
   Google Scholar
• Pincus T., Marcum S. B., Callahan L. F. Long‐term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second‐line drugs and prednisone. J Rheumatol 1992; 19: 1885–94
   PubMed Web of Science ®Google Scholar
• Kuiper S., van Gestel A. M., Swinkels H. L., de Boo T. M., da Silva J. A., van Riel P. L. Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis. J Rheumatol 2001; 28: 1809–16
   PubMed Web of Science ®Google Scholar
• Tengstrand B., Ahlmen M., Hafstrom I. The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. J Rheumatol 2004; 31: 214–22
   PubMed Web of Science ®Google Scholar
• OR R. E., Haugeberg G., Uhlig T., Mowinckel P., Falch J. A., Halse J. I., et al. Self reported non‐vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables. Ann Rheum Dis 2004; 63: 177–82
   PubMedGoogle Scholar
• O'Neill T. W., Felsenberg D., Varlow J., Cooper C., Kanis J. A., Silman A. J. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996; 11: 1010–18
   PubMed Web of Science ®Google Scholar
• Kroot E. J., Nieuwenhuizen M. G., de Waal Malefijt M. C., van Riel P. L., Pasker‐de Jong P. C., Laan R. F. Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum 2001; 44: 1254–60
   PubMed Web of Science ®Google Scholar
• Buckley L. M., Leib E. S., Cartularo K. S., Vacek P. M., Cooper S. M. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low‐dose corticosteroids in patients with rheumatoid arthritis. A randomized, double‐blind, placebo‐controlled trial. Ann Intern Med 1996; 125: 961–8
   PubMed Web of Science ®Google Scholar
• Haugeberg G., Orstavik R. E., Uhlig T., Falch J. A., Halse J. I., Kvien T. K. Bone loss in patients with rheumatoid arthritis: results from a population‐based cohort of 366 patients followed up for two years. Arthritis Rheum 2002; 46: 1720–8
   PubMed Web of Science ®Google Scholar
• Vis M., Voskuyl A. E., Wolbink G. J., Dijkmans B. A., Lems W. F. Bone mineral density in patients with rheumatoid arthritis treated with infliximab. Ann Rheum Dis 2005; 64: 336–7
   PubMedGoogle Scholar